MedTrace Logo

Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer

NCT00316433 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2007-04-05

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and effectiveness of the combination of oxaliplatin and irinotecan (CPT-11) in patients with previously untreated, advanced small cell lung cancer.

Conditions

Interventions

DRUG

Irinotecan (CPT-11)

DRUG

Oxaliplatin (Eloxatin)

Sponsors & Collaborators

  • Sanofi-Synthelabo

    collaborator INDUSTRY

  • Swedish Medical Center

    lead OTHER

Principal Investigators

  • Howard (Jack) West, MD · Swedish Medical Center Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Completion
2007-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00316433 on ClinicalTrials.gov